Repro Med Systems Inc (KRMD) - Net Assets
Based on the latest financial reports, Repro Med Systems Inc (KRMD) has net assets worth $16.46 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($27.10 Million) and total liabilities ($10.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Repro Med Systems Inc (KRMD) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.46 Million |
| % of Total Assets | 60.75% |
| Annual Growth Rate | 7.59% |
| 5-Year Change | -53.5% |
| 10-Year Change | 148.32% |
| Growth Volatility | 100.7 |
Repro Med Systems Inc - Net Assets Trend (1996–2024)
This chart illustrates how Repro Med Systems Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Repro Med Systems Inc for the complete picture of this company's asset base.
Annual Net Assets for Repro Med Systems Inc (1996–2024)
The table below shows the annual net assets of Repro Med Systems Inc from 1996 to 2024. For live valuation and market cap data, see how much is Repro Med Systems Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $16.81 Million | -17.39% |
| 2023-12-31 | $20.35 Million | -35.03% |
| 2022-12-31 | $31.33 Million | -14.18% |
| 2021-12-31 | $36.50 Million | +0.95% |
| 2020-12-31 | $36.16 Million | +221.79% |
| 2019-12-31 | $11.24 Million | +25.39% |
| 2018-12-31 | $8.96 Million | +16.83% |
| 2017-12-31 | $7.67 Million | +14.88% |
| 2016-12-31 | $6.68 Million | -1.40% |
| 2015-12-31 | $6.77 Million | +7.93% |
| 2014-12-31 | $6.27 Million | +20.83% |
| 2013-12-31 | $5.19 Million | +19.17% |
| 2012-12-31 | $4.36 Million | +22.70% |
| 2011-12-31 | $3.55 Million | +66.92% |
| 2010-12-31 | $2.13 Million | +105.81% |
| 2009-12-31 | $1.03 Million | +46.59% |
| 2008-12-31 | $705.09K | +217.07% |
| 2007-12-31 | $-602.26K | +6.75% |
| 2006-12-31 | $-645.83K | -13.34% |
| 2005-12-31 | $-569.82K | -49.85% |
| 2004-12-31 | $-380.26K | -119.22% |
| 2003-12-31 | $-173.46K | -383.50% |
| 2002-12-31 | $61.19K | -81.86% |
| 2001-12-31 | $337.38K | -51.42% |
| 2000-12-31 | $694.45K | +5.55% |
| 1999-12-31 | $657.91K | +21.83% |
| 1998-12-31 | $540.00K | -71.12% |
| 1997-12-31 | $1.87 Million | -13.82% |
| 1996-12-31 | $2.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Repro Med Systems Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2791804300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $493.78K | 2.94% |
| Other Components | $45.70 Million | 271.80% |
| Total Equity | $16.81 Million | 100.00% |
Repro Med Systems Inc Competitors by Market Cap
The table below lists competitors of Repro Med Systems Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Frauenthal Holding AG
VI:FKA
|
$188.60 Million |
|
OrganiGram Holdings Inc
TO:OGI
|
$188.68 Million |
|
Hawesko Holding AG
XETRA:HAW
|
$188.69 Million |
|
Sinphar Pharmaceutical Co Ltd
TW:1734
|
$188.76 Million |
|
Starrag Group Holding AG
SW:STGN
|
$188.48 Million |
|
Eastech Holding Limited
TW:5225
|
$188.47 Million |
|
Oriental Interest Bhd
KLSE:5827
|
$188.39 Million |
|
Gulf Island Fabrication Inc
NASDAQ:GIFI
|
$188.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Repro Med Systems Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 20,353,771 to 16,813,679, a change of -3,540,092 (-17.4%).
- Net loss of 6,066,633 reduced equity.
- Share repurchases of 97,379 reduced equity.
- Other factors increased equity by 2,623,920.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.07 Million | -36.08% |
| Share Repurchases | $97.38K | -0.58% |
| Other Changes | $2.62 Million | +15.61% |
| Total Change | $- | -17.39% |
Book Value vs Market Value Analysis
This analysis compares Repro Med Systems Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.09x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 143.05x to 11.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $0.03 | $4.07 | x |
| 2000-12-31 | $0.03 | $4.07 | x |
| 2001-12-31 | $0.01 | $4.07 | x |
| 2002-12-31 | $0.00 | $4.07 | x |
| 2003-12-31 | $-0.01 | $4.07 | x |
| 2004-12-31 | $-0.02 | $4.07 | x |
| 2005-12-31 | $-0.02 | $4.07 | x |
| 2006-12-31 | $-0.02 | $4.07 | x |
| 2007-12-31 | $-0.02 | $4.07 | x |
| 2008-12-31 | $0.02 | $4.07 | x |
| 2009-12-31 | $0.03 | $4.07 | x |
| 2010-12-31 | $0.06 | $4.07 | x |
| 2011-12-31 | $0.10 | $4.07 | x |
| 2012-12-31 | $0.12 | $4.07 | x |
| 2013-12-31 | $0.14 | $4.07 | x |
| 2014-12-31 | $0.17 | $4.07 | x |
| 2015-12-31 | $0.18 | $4.07 | x |
| 2016-12-31 | $0.18 | $4.07 | x |
| 2017-12-31 | $0.20 | $4.07 | x |
| 2018-12-31 | $0.23 | $4.07 | x |
| 2019-12-31 | $0.29 | $4.07 | x |
| 2020-12-31 | $0.86 | $4.07 | x |
| 2021-12-31 | $0.82 | $4.07 | x |
| 2022-12-31 | $0.70 | $4.07 | x |
| 2023-12-31 | $0.45 | $4.07 | x |
| 2024-12-31 | $0.37 | $4.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Repro Med Systems Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.03%
- • Asset Turnover: 1.24x
- • Equity Multiplier: 1.62x
- Recent ROE (-36.08%) is below the historical average (-12.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 38.04% | 12.12% | 1.31x | 2.39x | $184.51K |
| 2000 | -15.04% | -5.01% | 1.45x | 2.08x | $-173.90K |
| 2001 | -114.43% | -21.95% | 1.26x | 4.15x | $-419.81K |
| 2002 | -438.32% | -16.19% | 1.49x | 18.15x | $-274.31K |
| 2003 | 0.00% | -18.19% | 1.29x | 0.00x | $-260.65K |
| 2004 | 0.00% | -25.69% | 1.54x | 0.00x | $-362.87K |
| 2005 | 0.00% | -12.48% | 1.90x | 0.00x | $-160.83K |
| 2006 | 0.00% | -14.68% | 1.52x | 0.00x | $-190.14K |
| 2007 | 0.00% | -0.11% | 1.99x | 0.00x | $57.73K |
| 2008 | 146.20% | 29.97% | 1.49x | 3.28x | $960.35K |
| 2009 | 86.05% | 23.56% | 1.58x | 2.31x | $786.08K |
| 2010 | 33.10% | 14.31% | 1.60x | 1.45x | $491.36K |
| 2011 | 22.98% | 12.77% | 1.33x | 1.35x | $460.82K |
| 2012 | 16.66% | 9.35% | 1.39x | 1.28x | $290.10K |
| 2013 | 13.55% | 8.09% | 1.40x | 1.20x | $184.24K |
| 2014 | 12.00% | 6.70% | 1.54x | 1.16x | $125.77K |
| 2015 | 11.56% | 6.39% | 1.49x | 1.21x | $105.77K |
| 2016 | -8.01% | -4.35% | 1.50x | 1.22x | $-1.20 Million |
| 2017 | 14.16% | 6.80% | 1.72x | 1.21x | $318.98K |
| 2018 | 10.16% | 5.25% | 1.65x | 1.18x | $14.49K |
| 2019 | 5.02% | 2.44% | 1.67x | 1.24x | $-559.26K |
| 2020 | -3.35% | -5.01% | 0.61x | 1.10x | $-4.83 Million |
| 2021 | -12.50% | -19.42% | 0.57x | 1.13x | $-8.21 Million |
| 2022 | -27.65% | -31.05% | 0.66x | 1.35x | $-11.79 Million |
| 2023 | -67.51% | -48.18% | 1.00x | 1.40x | $-15.78 Million |
| 2024 | -36.08% | -18.03% | 1.24x | 1.62x | $-7.75 Million |
Industry Comparison
This section compares Repro Med Systems Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,863,507,886
- Average return on equity (ROE) among peers: -17.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Repro Med Systems Inc (KRMD) | $16.46 Million | 38.04% | 0.65x | $188.53 Million |
| Akoya Biosciences Inc (AKYA) | $121.35 Million | -35.38% | 0.57x | $64.44 Million |
| Align Technology Inc (ALGN) | $1.35 Billion | 32.89% | 0.86x | $12.66 Billion |
| AngioDynamics Inc (ANGO) | $517.03 Million | -1.36% | 0.37x | $444.32 Million |
| AptarGroup Inc (ATR) | $2.71 Billion | 14.48% | 0.94x | $7.66 Billion |
| AtriCure Inc (ATRC) | $16.74 Million | -22.66% | 1.01x | $1.44 Billion |
| Avinger Inc (AVGR) | $-73.64 Million | 0.00% | 0.00x | $1.52 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $10.52 Million | -163.15% | 1.04x | $156.14 Million |
| Avantor Inc (AVTR) | $5.57 Billion | -9.53% | 1.12x | $5.43 Billion |
| Azenta Inc (AZTA) | $553.69 Million | -12.55% | 0.24x | $1.04 Billion |
| Baxter International Inc (BAX) | $7.87 Billion | 19.65% | 1.00x | $8.85 Billion |
About Repro Med Systems Inc
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating p… Read more